Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
出版年份 2020 全文链接
标题
Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
作者
关键词
-
出版物
Frontiers in Immunology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-09-10
DOI
10.3389/fimmu.2020.02048
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Microsatellite instability: a review of what the oncologist should know
- (2020) Kai Li et al. Cancer Cell International
- Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
- (2020) Henna Kasanen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
- (2020) Tina Krieger et al. Diagnostic Pathology
- Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma
- (2020) Wang Li et al. Oncology Letters
- Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma
- (2020) S. S. Jeske et al. Immunity & Ageing
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer
- (2019) Carter Barger et al. Cancers
- Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma
- (2019) Sheng Yang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma
- (2019) Qi-Feng Chen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Eight key long non-coding RNAs predict hepatitis virus positive hepatocellular carcinoma as prognostic targets
- (2019) Zi-Lin Huang et al. World Journal of Gastrointestinal Oncology
- Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
- (2019) Hao-Xiang Wu et al. Annals of Translational Medicine
- DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
- (2019) Huimin Dan et al. OncoTargets and Therapy
- Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
- (2018) Di Jia et al. Aging-US
- Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis
- (2018) Claudia Cava et al. BMC GENOMICS
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
- (2018) Franz X. Schaub et al. Cell Systems
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hippo Pathway Kinase Mst1 Is Required for Long-Lived Humoral Immunity
- (2018) Sahar Bagherzadeh Yazdchi et al. JOURNAL OF IMMUNOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
- (2017) Yingyan Yu Frontiers of Medicine
- Gene expression markers of Tumor Infiltrating Leukocytes
- (2017) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
- (2017) Nathan O. Siemers et al. PLoS One
- ExtendedRASGene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
- (2016) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures
- (2016) Zhen Cao et al. Scientific Reports
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenomic agreement between two cancer cell line data sets
- (2015) Nicolas Stransky et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Somatic mutation in cancer and normal cells
- (2015) I. Martincorena et al. SCIENCE
- Prioritizing targets for precision cancer medicine
- (2014) F. Andre et al. ANNALS OF ONCOLOGY
- mTOR inhibition improves immune function in the elderly
- (2014) J. B. Mannick et al. Science Translational Medicine
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inferring tumour purity and stromal and immune cell admixture from expression data
- (2013) Kosuke Yoshihara et al. Nature Communications
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started